These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
519 related articles for article (PubMed ID: 23966418)
1. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Schmid AW; Fauvet B; Moniatte M; Lashuel HA Mol Cell Proteomics; 2013 Dec; 12(12):3543-58. PubMed ID: 23966418 [TBL] [Abstract][Full Text] [Related]
2. Phosphorylated α-synuclein as a potential biomarker for Parkinson's disease and related disorders. Foulds P; Mann DM; Allsop D Expert Rev Mol Diagn; 2012 Mar; 12(2):115-7. PubMed ID: 22369370 [No Abstract] [Full Text] [Related]
3. Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein. Zhang S; Zhu R; Pan B; Xu H; Olufemi MF; Gathagan RJ; Li Y; Zhang L; Zhang J; Xiang W; Kagan EM; Cao X; Yuan C; Kim SJ; Williams CK; Magaki S; Vinters HV; Lashuel HA; Garcia BA; James Petersson E; Trojanowski JQ; Lee VM; Peng C Nat Neurosci; 2023 Feb; 26(2):213-225. PubMed ID: 36690898 [TBL] [Abstract][Full Text] [Related]
4. Posttranslational Modifications of Hassanzadeh K; Liu J; Maddila S; Mouradian MM Pharmacol Rev; 2024 Oct; 76(6):1254-1290. PubMed ID: 39164116 [No Abstract] [Full Text] [Related]
5. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Simonsen AH; Kuiperij B; El-Agnaf OM; Engelborghs S; Herukka SK; Parnetti L; Rektorova I; Vanmechelen E; Kapaki E; Verbeek M; Mollenhauer B Biomark Med; 2016; 10(1):19-34. PubMed ID: 26314196 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206 [TBL] [Abstract][Full Text] [Related]
7. Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers. Murueta-Goyena A; Cipriani R; Carmona-Abellán M; Acera M; Ayo N; Del Pino R; Tijero B; Fernández-Valle T; Gabilondo I; Zallo F; Matute C; Sánchez-Pernaute R; Khurana V; Cavaliere F; Capetillo-Zarate E; Gómez-Esteban JC Parkinsonism Relat Disord; 2022 Mar; 96():29-35. PubMed ID: 35149357 [TBL] [Abstract][Full Text] [Related]
8. Development of a Novel Electrochemiluminescence ELISA for Quantification of α-Synuclein Phosphorylated at Ser Dutta S; Hornung S; Taha HB; Biggs K; Siddique I; Chamoun LM; Shahpasand-Kroner H; Lantz C; Herrera-Vaquero M; Stefanova N; Loo JA; Bitan G ACS Chem Neurosci; 2023 Apr; 14(7):1238-1248. PubMed ID: 36920792 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis. Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011 [TBL] [Abstract][Full Text] [Related]
11. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Oueslati A; Fournier M; Lashuel HA Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318 [TBL] [Abstract][Full Text] [Related]
12. Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications. Vicente Miranda H; Xiang W; de Oliveira RM; Simões T; Pimentel J; Klucken J; Penque D; Outeiro TF J Neurochem; 2013 Sep; 126(5):673-84. PubMed ID: 23534813 [TBL] [Abstract][Full Text] [Related]
13. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease. O'Hara DM; Kalia SK; Kalia LV Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096 [TBL] [Abstract][Full Text] [Related]
14. Pathological biochemistry of alpha-synucleinopathy. Iwatsubo T Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483 [TBL] [Abstract][Full Text] [Related]
16. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984 [TBL] [Abstract][Full Text] [Related]
17. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease. Yoo H; Lee J; Kim B; Moon H; Jeong H; Lee K; Song WJ; Hur JK; Oh Y BMB Rep; 2022 Jul; 55(7):323-335. PubMed ID: 35733294 [TBL] [Abstract][Full Text] [Related]
18. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965 [TBL] [Abstract][Full Text] [Related]
19. Targeting α-synuclein post-translational modifications in Parkinson's disease. Canever JB; Soares ES; de Avelar NCP; Cimarosti HI Behav Brain Res; 2023 Feb; 439():114204. PubMed ID: 36372243 [TBL] [Abstract][Full Text] [Related]
20. The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches. Al-Mansoori KM; Hasan MY; Al-Hayani A; El-Agnaf OM Curr Alzheimer Res; 2013 Jul; 10(6):559-68. PubMed ID: 23899170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]